Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Date:12/10/2010

s of Health Registry indicate that without treatment, patients in the United States with PAH have a median survival time of approximately three years from diagnosis.

About APD811APD811, a potent and selective agonist (or activator) of the prostacyclin receptor, is Arena's internally discovered drug candidate for the treatment of PAH. Prostacyclin receptor agonists, through regulation of vascular smooth muscle tone, improve mortality and exercise tolerance in PAH patients and are among the treatments administered as standard of care for advanced PAH. Currently available prostacyclin receptor agonists belong to the prostanoid class of molecules and these products need to be administered frequently or continuously through intravenous, subcutaneous or inhaled routes. Arena believes that APD811, as a non-prostanoid prostacyclin agonist, has the potential to improve the standard of care for PAH by providing an oral form of administration with clinical benefits similar to currently available prostacyclin receptor agonists.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include s
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... tells her story but sometimes showing a few less chapters ... quest continues for new ways to keep skin looking its ... survey commissioned by Ulthera ® (the manufacturer of the ... a non-invasive lift indication), 83 percent of women admitted they ...
... Boston Scientific Corporation (NYSE: BSX ) today ... the 60th Annual Scientific Session of the American College ... "Twelve-month results from the PLATINUM Workhorse clinical ... Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to ...
Cached Medicine Technology:What Would Women Give Up for a More Youthful Face? 2What Would Women Give Up for a More Youthful Face? 3Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... The Honor ... Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San ... to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently ... know in predictive health analytics , Jvion continues to disrupt the predictive ... predictive software that targets patient and population level illness to drive prevention and ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being ... meal, making July the most appropriate to be National Hot Dog Month. King Kullen ... the next cookout different than the ones in the past. Celebrate National Hot Dog ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... plays a surprising role reducing the level of infection caused ... cancer patients and others with weakened immune systems. The ... fungal evaders by enhancing the body,s ability to chew them ... where it would continue to provoke an onslaught of harmful ...
... August 19, 2010The first successful report of using cell-depleted lung ... from embryonic stem cells is presented in a breakthrough article ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). The ... Embryonic stem cells (ESCs) have the potential to mature into ...
... doctoral student Lisa Carter-Harris has received the Johnson & ... Colleges of Nursing Minority Nursing Faculty Scholarship for the ... to graduate nursing students from minority backgrounds who agree ... , The AACN will hold $1,500 to cover expenses ...
... A recent study by researchers at Penn State College of ... lupus erythematosus (SLE) patients at the time of hospital admission ... women were youngest to both be admitted with CVD and ... the study appear in the September issue of Arthritis ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Fibromyalgia sufferers ... tai chi, new research finds. Researchers divided 66 people ... of tai chi twice a week for 12 weeks; the ... stretching. At the end of 12 weeks, the ...
... A team of University of Michigan scientists has found ... roundworms. Scientists who study aging have long known that significantly ... is to find less drastic ways to achieve the same ... evidence that scientists may succeed at finding targets for drugs ...
Cached Medicine News:Health News:Old drug holds promise against opportunistic lung bug 2Health News:Old drug holds promise against opportunistic lung bug 3Health News:Old drug holds promise against opportunistic lung bug 4Health News:Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells 2Health News:UofL student wins national minority nursing scholarship 2Health News:Black women with SLE develop cardiovascular disease at early age 2Health News:Black women with SLE develop cardiovascular disease at early age 3Health News:Tai Chi May Help Ease Fibromyalgia 2Health News:Tai Chi May Help Ease Fibromyalgia 3Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: